0000899243-20-013929.txt : 20200521 0000899243-20-013929.hdr.sgml : 20200521 20200521210351 ACCESSION NUMBER: 0000899243-20-013929 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200420 FILED AS OF DATE: 20200521 DATE AS OF CHANGE: 20200521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAWES KAREN A CENTRAL INDEX KEY: 0001261506 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 20903453 MAIL ADDRESS: STREET 1: 579 BELLEVUE AVE CITY: NEWPORT STATE: RI ZIP: 02840 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-04-20 2020-04-22 0 0000730272 REPLIGEN CORP RGEN 0001261506 DAWES KAREN A C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 1 0 0 0 Common Stock 2020-04-20 4 M 0 8200 3.30 A 121234 D Common Stock 2020-04-20 4 S 0 3202 104.98 D 118032 D Common Stock 2020-04-20 4 S 0 8998 104.42 D 109034 D Common Stock 2020-04-21 4 M 0 11800 3.30 A 120834 D Stock Option (Right to Buy) 3.30 2020-04-20 4 M 0 8200 0.00 D 2020-09-16 Common Stock 8200 11800 D Stock Option (Right to Buy) 3.30 2020-04-21 4 M 0 11800 0.00 D 2020-09-16 Common Stock 11800 0 D Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. $104.98 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.73 to $105.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. $104.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.72 to $104.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option is currently exercisable This Form 4/A amends the Form 4 filed on April 22, 2020 solely to correct the date of the Reporting Person's 10(b)5-1 trading plan. /s/ Jeffrey P. Leduc (Attorney in Fact) 2020-05-21